A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC
Latest Information Update: 07 Jul 2025
At a glance
- Drugs Catequentinib (Primary) ; Tislelizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 29 Jun 2025 Planned initiation date changed from 7 May 2025 to 20 Jul 2025.
- 25 May 2025 New trial record